Abstract: In an embodiment of the present disclosure there is provided a method of inactivating enveloped DNA virus particles in a biological sample. In an embodiment, such a method comprises contacting the biological sample with an effective amount of an antiviral composition comprising PD 404,182 In some embodiments, the DNA virus is the Herpes Simplex virus-1 (HSV-1) or the Herpes Simplex Virus-2 (HSV-2). In another embodiment of the present disclosure, there is provided a method of treating, preventing, or reducing a viral infection caused by an enveloped DNA virus in a subject in need thereof. In yet another embodiment, there is provided a method of preventing transmission of a viral infection to a subject in need thereof.

Abstract: In some embodiments the present disclosure provides a method of inactivating a RNA virus of the family retroviridae in a biological sample. Such a method comprises contacting the biological sample with an effective amount of an antiviral composition comprising PD 404,182. In an embodiment of the present disclosure the RNA virus is selected from the group consisting of HIV pseudotyped lentiviruses, primary human immunodeficiency virus-1 isolates (HIV-1), human immunodeficiency virus-2 (HIV-2), and simian immunodeficiency virus (SIV). Further embodiments of the present disclosure pertain to a method of treating a subject infected by a RNA virus of the family retroviridae. Another embodiment of the present invention pertains to a method of preventing transmission of a RNA virus of the family retroviridae in a subject in need thereof.